Blood pressure changes over 3 years in a resistant severe hypertensive crisis population - sub project

Project Details

Aim: The aim of this sub project is to detail the prevalence and determinants of MAFLD and CLD risk factors and liver fibrosis in a primary care population.  To determine the accuracy of FIB-4 performed in primary care in the prediction of liver-related events (decompensation and HCC).  And to identify at-risk populations in primary care in whom a FIB-4 based screening approach should be used to predict risk of future liver-related events.

Overview: Metabolic dysfunction associated fatty liver disease (MAFLD) is the most common chronic liver disease (CLD) globally, and a leading cause of cirrhosis and its complications of liver failure and hepatocellular carcinoma (HCC).  Effective pharmacotherapy is likely to available in the near future, however identifying patients who will benefit remains a challenge.  The bulk of disease burden exists in primary care however there is a lack of knowledge regarding the prevalence of underlying liver disease risk factors and liver fibrosis in this population. Furthermore, which risk-factor profiles should be targeted for further assessment remains uncertain and knowledge regarding the performance of non-invasive tests (NIT’s) that predict liver-related outcomes in primary care is limited.  These knowledge gaps regarding the identification of at-risk patients and understanding the real-world burden of disease has clear implications for patient care, health policy and funding of interventions.

In order to address these gaps we will take advantage of three data-sets stemming from MRFF-funded investigator initiated clinical trials examining fibrosis assessment in primary care (the IC3 trial, and the IDEAL Care trial) and a large linked primary care data-set (Patron).

Patron ID: PAT1067

Project Lead: Jon Emery